Octave

Octave is on a mission to change the paradigm of care in neurodegenerative disease, starting with multiple sclerosis (MS).
#MultipleSclerosis #MS #PrecisionCare

[MSJ @MSJ_Research]

#WorldMSDay #MyMSDiagnosis Top trending paper in the past 12 months:

Discontinuation of #MultipleSclerosis treatments (if age >55y, RRMS >5 years, and no relapses for 5 years) reduces costs, but increases relapses after 1 year (from @OctaveBio).
🔽
https://t.co/G6JOe5jght

[Octave @OctaveBio]

Proud to be recognized @MedTech_Award’s “Best Care Management Platform” highlighting how we are changing the paradigm of care with our #precisionmedicine solution for #MS. Learn More: https://t.co/Ei8MI5E15k

[Octave @OctaveBio]

We are thrilled to welcome Jeron Evans and Debbie Ledet to our leadership team. With their deep expertise in commercial expansion and scale, we are ready to accelerate our growth and deliver our #PrecisionCare Solution to more patients.  Read more https://t.co/lxErbtpyqN

[Octave @OctaveBio]

@OctaveBio is proud to have had 7 posters featured @ACTRIMS Forum 2024. Check out all of Octave's posters by visiting https://t.co/eTboRV4uwU

[Octave @OctaveBio]

Attending #ACTRIMSForum 2024?

Don't miss Octave & our collaborators at the poster presentations:

1️⃣ Poster Session 1
🕕 Thu. February 29, 6:00 - 7:30pm

2️⃣ Poster Session 2
🕕 Fri. March 1, 6:00 - 7:30pm

➡️ Visit us at Pod #631 or online: https://t.co/KR05F5SFS0

#ACTRIMS

[Octave @OctaveBio]

Meet Octave at #ACTRIMSForum 2024, Feb 29 – Mar 2!

Discover how the Multiple Sclerosis Disease Activity (MSDA) Test is delivering actionable insights for more confident #MScare management.

➡️ Visit us at Pod 631 or schedule your meeting: https://t.co/N9QiJrb1jI

[Octave @OctaveBio]

Octave is excited to be a part of #ACTRIMSForum 2024! ✈️

Join us at @ACTRIMS, Feb 29 – Mar 2 to learn how we're changing the paradigm of care in #MultipleSclerosis (MS) with our MS #PrecisionCare Solution.

➡️ Stop by Pod #631 or schedule your meeting: https://t.co/X5WGzAk4rq

[Octave @OctaveBio]

Thrilled to announce the launch of our dedicated patient webpage! 🌐︎

Designed with patients in mind, this comprehensive webpage provides easy access to valuable information about our multiple sclerosis (MS) Precision Care Solution.

Learn more: https://t.co/I4jA2nQl7L

[Octave @OctaveBio]

With current tools, changes in #MultipleSclerosis (MS) disease activity are often complicated to detect. Move from the subjectivity of clinical assessments and periodic MRIs to a more convenient, objective, biological measurement.

Learn more: https://t.co/Ph45qTGBMr

[Octave @OctaveBio]

Join us & @OlinkProteomics at PMWC - #PrecisionMedicine World Conference to hear Ferhan Qureshi present "Bridging Proteomics to the Clinic: A Multivariate Blood Test for Disease Activity in MS" at 9:45 a.m. PT on Thursday, Jan. 25 in the Showcase Track S2. https://t.co/e3WpaaF5g4

[ICR @ICRPR]

“When I saw the opportunity I said, ‘wow, there is something here to impact patients, across the ecosystem, across the world.” Listen in on @TomRyanICR's conversation with @Octavebio CCO Maital Rasmussen on this week's episode of #WelcomeToTheArena: https://t.co/4gwQD1xy8Y

[Octave @OctaveBio]

Attending the @jpmorgan Healthcare Conference in #SanFrancisco?

Hear from @msrasmussen Octave's CCO for "The New Faces of Precision Medicine: Technology, AI, and Diversity-Driven Innovation to Reality."

Schedule a meeting: https://t.co/ARp4Z5hPU4

#JPM2024 @goodwinlaw @KPMG

[Octave @OctaveBio]

🚀 Exciting News! We're delighted to announce the launch of our new Instagram page, @OctaveBio, dedicated to sharing news, education & most importantly the stories of the incredible people at the heart of our work: #patients.

Follow us: https://t.co/lQDCxo79B6

[Octave @OctaveBio]

Seasons greetings and #HappyHolidays from the Octave team! ❄️

As we pause to reflect on 2023, we're filled with gratitude for our team and partners who share our commitment to advancing #NeurodegenerativeDisease care, starting with #MultipleSclerosis.

[Octave @OctaveBio]

The Journal of Clinical Pathways published an article detailing the Octave quadruple-aim framework to positively impact patient care and lower costs. https://t.co/fKTXHQXTad

[Octave @OctaveBio]

At Octave, we are proud to continue our commitment to the community by partnering with Family Giving Tree to spread kindness by delivering specifically wished for gifts.

🎁 Join us in making a difference: https://t.co/4tj2hqBPiT

[Octave @OctaveBio]

Octave's Multiple Sclerosis Disease Activity (MSDA) Test is in routine clinical use among clinicians as a valuable tool for managing patients with #MultipleSclerosis (MS), & is currently used by MS clinics around the country.

Read more in @GenomeWeb ➡️ https://t.co/u3l4FdNxD7

[Octave @OctaveBio]

Octave announces Chairman of the Board, CEO transition in preparation for accelerated commercial growth and increased patient access. William Hagstrom, will transition to Chairman of the Board, and Doug Biehn is appointed President & CEO.
https://t.co/b8raQW8izf

[Octave @OctaveBio]

Thank you @MedtechInsight1 for profiling @OctaveBio's #biomarker work in #Parkinson and our $10 million grant from @MichaelJFoxOrg https://t.co/RI6pScKPHm

[Octave @OctaveBio]

What type of content do you find most valuable?